Stocks analysis

A vs AFL Stock Comparison

Scores Breakdown

Metric A AFL
📈 Growth 26/30 6/30
💰 Profitability 17/20 18/20
🏦 Financial Health 15/20 15/20
💵 Valuation 16/20 12/20
⚠️ Risk (lower is better) 5/10 7/10
Overall Score 79/100 54/100

Side-by-Side Summaries

A Analysis AFL Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

  • Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
  • Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Eight quarters show a revenue path from $5.403B (2024 Q3) to $4.117B (2026 Q2). A trough occurred in 2025 Q1 with $4.16B rev and $29M net income. Revenues then recovered to the high 4.7–4.9B range in 2025 H2, before easing again to $4.12B in 2026 Q2. Net income moved from $1.902B (2024 Q3) to $0.825B (2026 Q2), with a dip to $29M in 2025 Q1. Overall, the trend is negative on revenue and earnings, but several quarters display strong operating performance (notably 2024 Q3 and late-2025/2026).

💰 Margins & Cash Flow

Operating margins were robust on several quarters, averaging in the mid-60s percent, peaking around 75% in 2024 Q3 and hovering near 70% in late 2025–2026; a trough around 40–41% occurred in 2025 Q2. Cash flow from operations remained positive across periods (e.g., $315M in 2024 Q4, $1.27B in 2025 Q3, $112M in 2026 Q2), while investing/financing swings produced occasional negative free cash flow (notably 2025 Q1 and 2026 Q1).

🛡️ Balance Sheet & Liquidity

Current assets consistently exceed current liabilities (e.g., 2026 Q2: Current Assets $115.96B vs Current Liabilities $85.65B). Total assets run in the $116–$125B range with equity around $28–$30B, indicating a solid reserve position given insurer-liability balances. Leverage remains typical for an insurance franchise, with ample liquidity cushions.

⚠️ Key Drivers & Risks

  • Drivers: Stable insurance premium streams and investment income support, with favorable rate environments aiding capital generation.
  • Risks: Earnings volatility from reserve dynamics and regulatory shifts; sensitivity to interest-rate changes and macro cycle could compress margins during downturns.